Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in China. Some patients respond poorly to conventional immunosuppressive therapy and are prone to developing refractory disease. Budesonide enteric-coated capsules, a novel immunomodulatory agent that targets intestinal mucosal B cells, offer a new therapeutic option for these patients.
We report the case of a middle-aged male patient diagnosed with IgA nephropathy (focal segmental glomerulosclerosis) by renal biopsy. The disease had persisted for approximately 14 years, presenting with proteinuria (1–2.16 g/d) and impaired renal function (serum creatinine: 130–150 μmol/L).The patient underwent stepwise intensified immunosuppressive therapy comprising systemic glucocorticoids, tripterygium glycosides, and mycophenolate mofetil combined with telitacicept, along with supportive treatments including renin–angiotensin system (RAS) inhibitors, sodium–glucose cotransporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRAs).Despite these interventions, the patient’s 24-hour urinary protein remained above 1 g/d and serum creatinine exceeded 170 μmol/L. Therefore, the immunosuppressive regimen was adjusted to budesonide enteric-coated capsules (16 mg/d) combined with methylprednisolone (16 mg/d). At week 9, the dose of methylprednisolone was reduced to 8 mg/d.
After approximately 8 months of treatment, the patient’s 24-hour urinary protein markedly decreased from 1.415 g/d to 0.848 g/d, while renal function improved and remained stable (serum creatinine decreased from 181 μmol/L to 168 μmol/L). No adverse reactions associated with budesonide enteric-coated capsules were observed.
Budesonide enteric-coated capsules combined with intensive supportive therapy can effectively improve renal outcomes in patients with refractory and progressive IgA nephropathy who do not respond to multiple immunosuppressive regimens. As an etiology-targeted therapeutic agent acting on intestinal mucosal immunity by modulating the number and activity of B cells, budesonide enteric-coated capsules can induce proteinuria remission, stabilize renal function, and demonstrate a favorable safety profile, making it a promising salvage treatment option for this patient population.
